1. Introduction {#sec1-cancers-11-00598}
===============

Approximately 3% of all cancers occur in the oral cavity; approximately 90% of all oral cancers (OCs) are oral squamous cell carcinoma (OSCC), which is one of the most prevalent cancers and the fourth commonest causes of cancer mortality among men in Taiwan \[[@B1-cancers-11-00598]\]. Despite advancements in the diagnosis and treatment of OSCC, the 5-year overall survival (OS) rate, which is currently 56.6%, has not improved significantly in the past decades \[[@B1-cancers-11-00598]\]. This is mainly because approximately 51.5% of OSCC cases are diagnosed at advanced stages (III and IV) \[[@B1-cancers-11-00598]\]. For the early stages, namely stages I and II, surgery constitutes the standard treatment of choice and often results in a permanent cure. Adjuvant treatments of chemotherapy and radiotherapy (RT) with surgery are used to treat advanced stages of OSCC, depending on the overall health status of the patients and invasive pathological parameters \[[@B2-cancers-11-00598],[@B3-cancers-11-00598]\]. Despite aggressive therapy, the 5-year survival rate among patients with advanced stages of OSCC is low, and most patients die in the first 30 months of the disease \[[@B4-cancers-11-00598],[@B5-cancers-11-00598]\]. The clinical outcomes of OSCC often vary with factors related to the tumor and treatment \[[@B6-cancers-11-00598]\]. However, inherent patient genetic characteristics may affect patient prognosis \[[@B7-cancers-11-00598]\].

The response of tumor cells to DNA damage involves numerous complicated molecular mechanisms \[[@B8-cancers-11-00598],[@B9-cancers-11-00598]\]. For example, DNA repair mechanisms can affect the survival of tumor cells. Both chemotherapy and RT induce DNA lesions, including replication errors, thereby activating the DNA damage and repair response \[[@B10-cancers-11-00598]\]. The DNA mismatch repair (MMR) pathway proteins, which include MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), MutS homolog 3 (MSH3), and exonuclease 1 (EXO1), play significant roles in the repair process by recognizing DNA damage caused by endogenous and exogenous agents \[[@B11-cancers-11-00598],[@B12-cancers-11-00598]\]. MSH2, which dimerizes with other proteins (MSH6 or MSH3), and are responsible for recognizing and initiating the mismatch repair. The MLH1 protein joins another protein (MLH4) to form a protein complex that coordinates downstream repair events, which involves the EXO1 protein \[[@B12-cancers-11-00598]\]. Genetic variations in MMR genes alter the capacity of individuals to repair DNA damage induced by radiotherapeutic and chemotherapeutic agents, leading to variations in outcomes ranging from tumor cell apoptosis to resistance \[[@B13-cancers-11-00598],[@B14-cancers-11-00598]\]. For example, the G-alleles of *MLH1* rs1800734 \[[@B15-cancers-11-00598]\], *MSH3* rs26279 \[[@B14-cancers-11-00598],[@B16-cancers-11-00598]\], and *EXO1* rs1047840 \[[@B14-cancers-11-00598]\] have been reported to be associated with higher levels of protein expression and/or higher survival rates than the variant alleles. Thus, the G-alleles represent higher DNA repair capacity than the other alleles, indicating that these single-nucleotide polymorphisms (SNPs) may have the potential to become prognostic biomarkers for individualized therapy.

Studies on the effects of genetic variations in MMR genes on the prognosis of cancer have generally included patients receiving different treatments and/or patients with different ethnic backgrounds \[[@B14-cancers-11-00598],[@B16-cancers-11-00598],[@B17-cancers-11-00598],[@B18-cancers-11-00598]\]. Given that different treatments may cause varying DNA damage and exhibit different repair efficacy, we investigated the association between polymorphisms and outcomes in OSCC patients who received identical treatment with adjuvant concurrent chemoradiotherapy (CCRT) and exhibited similar disease stages. Five SNPs of *MSH2*, *MSH3*, *EXO1,* and *MLH1* were selected according to their effects on the risk and/or survival of tumors \[[@B14-cancers-11-00598],[@B16-cancers-11-00598],[@B19-cancers-11-00598],[@B20-cancers-11-00598]\].

2. Results {#sec2-cancers-11-00598}
==========

In this study, 319 male patients with OSCC were recruited to explore the effects of genetic variants of MMR genes on the risk of death or recurrence. Their demographic and clinical parameters were evaluated ([Table 1](#cancers-11-00598-t001){ref-type="table"}). The mean (± standard deviation) age of the participants was 49.72 (± 9.8) years, and approximately half (48.59%) of the patients were ≥50 years old. Most of the participants were of Taiwanese ethnicity (72.1%), had normal body mass index (BMI) (49.22%), and reported that they had ever smoked cigarettes (85.27%), drank alcohol (69.28%), and chewed betel quid (86.21%). The participants who exhibited poor tumor characteristics comprised 17.24% with poor tumor differentiation, 61.76% with a primary tumor size corresponding to the T3--T4 range, 55.49% with perineural invasion, 5.96% with vascular invasion, 12.54% with lymphatic invasion, 64.26% with extranodal extension (ENE), and 86.83% with pathological tumor, nodes, and metastasis (TNM) stage IV.

The maximum follow-up period was 199 months with median follow-up times of 16 and 13 months for OS and disease-free survival (DFS), respectively. For the entire follow-up duration, 94 patients (29.5%) and 129 patients (40.4%) experienced events of death and recurrence, respectively. In the univariate analysis, clinicopathological characteristics, such as nodal involvement in the N2--N3 range (hazard ratio (HR) = 2.38, 95% confidence intervals (CI) = 1.43--3.94; *p* = 0.0008), lymphatic invasion (HR = 2.22, 95% CI = 1.32--3.72; *p* = 0.003), and ENE (HR = 3.78, 95% CI = 2.14--6.68; *p* \< 0.001), were associated with poor OS, and primary tumor size in the T3--T4 range (HR = 1.47, 95% CI = 1.03--2.09; *p* = 0.034), nodal involvement in the N2--N3 range (HR = 1.76, 95% CI = 1.17--2.63; *p* = 0.006), and ENE (HR = 1.87, 95% CI = 1.26--2.78; *p* = 0.002) were associated with poor DFS ([Table 2](#cancers-11-00598-t002){ref-type="table"}).

Furthermore, univariate candidate SNP analysis revealed that *MSH2* rs3732183 GG genotype (codominant model: HR = 0.47, 95% CI = 0.22--0.97; *p* = 0.042 and recessive model: HR = 0.46, 95% CI = 0.22--0.94; *p* = 0.034) was a more favorable prognostic factor for predicting DFS than was the AA genotype. The *EXO1* rs1047840 AA (recessive model: HR = 2.80, 95% CI = 1.02--7.66; *p* = 0.045) genotype was associated with a significantly increased risk of recurrence than the wild-type genotype ([Table 3](#cancers-11-00598-t003){ref-type="table"}). In addition, the *MLH1* rs1800734 GG genotype (codominant model: HR = 0.59, 95% CI = 0.33--1.06; *p* = 0.077) was associated with a slightly but insignificantly lower risk of DFS than the AA genotype. Although the *MSH3* polymorphisms were not significantly associated with survival, the linkage disequilibrium (LD) analysis show that *MSH3* rs12515548 and rs26279 were in high LD with each other (D' = 0.97 and R^2^ = 0.94) ([Figure S1](#app1-cancers-11-00598){ref-type="app"}). Therefore, only the missense SNP (rs26279) was used in further analysis.

[Figure 1](#cancers-11-00598-f001){ref-type="fig"} shows the Kaplan--Meier analysis and log-rank test results of the OS and DFS curves for selected SNPs in the OSCC patients who received CCRT. A borderline significant difference was observed in the DFS time but not in the OS time among the *MSH2* rs3732183 genotypes. The individuals with the GG genotype exhibited better DFS time than the individuals with other genotypes (log-rank test *p* = 0.0887) ([Figure 1](#cancers-11-00598-f001){ref-type="fig"} (A-1,A-2)). However, no significant difference in OS time was observed among the individuals with the *MLH1* rs1800734 genotypes ([Figure 1](#cancers-11-00598-f001){ref-type="fig"} (B-1,B-2)).

[Table 4](#cancers-11-00598-t004){ref-type="table"} shows the final multivariable model including demographic, clinical, and genetic factors for OS and DFS, respectively. The presence of ENE (HR = 2.91, 95% CI = 1.58--5.34, *p* = 0.006) was associated with a relatively high mortality risk. Patients of Mainland Chinese ethnicity (HR = 1.99, 95% CI = 1.04--3.82; *p* = 0.039), primary tumor size in the T3--T4 range (HR = 1.88, 95% CI = 1.19--2.98; *p* = 0.007), and nodal involvement in the N2--N3 range (HR = 1.96, 95% CI = 1.04--3.69; *p* = 0.038) were associated with an increased risk of recurrence. The GG genotype of *MLH1* rs1800734 was associated with borderline statistically significant longer OS (codominant model: HR = 0.52, 95% CI = 0.27--1.01; *p* = 0.054). The GG genotypes of *MSH2* rs3732183 (codominant model: HR = 0.45, 95% CI = 0.22--0.96; *p* = 0.039) and *MLH1* rs1800734 (codominant model: HR = 0.49, 95% CI = 0.26--0.92; *p* = 0.028) were favorable prognostic predictors of DFS.

3. Discussion {#sec3-cancers-11-00598}
=============

The MMR is a complicated network with numerous functions. One prominent function is genomic stability, which is achieved by eliminating mismatched or distorted DNA strands. SNPs in this pathway are shown to alter the anticancer effects of therapeutic agents. Therefore, identifying such SNPs may determine prognostic markers in patients with OSCC. In this retrospective cohort study, we investigated the association between genetic variants of MMR genes and clinical outcomes in the patients with OSCC who received adjuvant CCRT. The results indicated that the *MSH2* rs3732183 GG genotype was a favorable prognostic indicator of relapse, and the *MLH1* rs1800734 GG genotype was a favorable prognostic indicator of both relapse and death. In addition, patients with ENE exhibited a high risk of death, while those of Mainland Chinese ethnicity, with primary tumor size in the T3--T4 range and nodal involvement in the N2--N3 range exhibited high risks of relapse.

*MSH2* is a prominent member of the MMR pathway, and its inactivation can have far-reaching pathological effects on DNA. Studies have reported that polymorphisms in this gene affect the DNA damage and repair mechanism \[[@B14-cancers-11-00598],[@B21-cancers-11-00598]\]. Similarly, we found that variations in *MSH2* affected clinical outcomes in patients with OSCC. Patients with the rs3732183 GG genotype exhibited a lower risk of relapse than the patients with the AA genotype. The SNP rs3732183 is an intronic SNP that may affect MSH2 expression through cis-acting regulatory elements (such as enhancers, silencers, insulators, and transcription factors) that positively control gene expression \[[@B22-cancers-11-00598]\]. The A to G substitution may result in high MSH2 expression, which is favorable to the anticancer effects of therapeutic agents, thus reducing the risk of relapse. Low expression levels of MSH2 were previously found to have unfavorable prognostic value for different cancers, including head and neck squamous cell carcinoma (HNSCC) \[[@B18-cancers-11-00598],[@B23-cancers-11-00598],[@B24-cancers-11-00598]\]. Huang et al. reported MSH2 overexpression to correlate with better survival in Taiwanese colon cancer patients \[[@B25-cancers-11-00598]\]. Alternatively, the SNP may be in high linkage disequilibrium with other nearby polymorphisms that may affect MSH2 expression. Previously, Kang et al., in their study on Korean colorectal cancer patients, also reported the GG genotype of rs3732183 to show a favorable prognostic factor for DFS \[[@B26-cancers-11-00598]\].

Consistent with the results of previous studies \[[@B7-cancers-11-00598],[@B27-cancers-11-00598]\], we also observed that the carriers of the *MLH1* rs1800734 GG genotype exhibited lower risks of relapse and death than did the carriers of the wild-type AA genotype. The SNP rs1800734 is located at an *MLH1* promoter CpG island transcription factor-binding site that can cause differences in individual susceptibility by regulating the activity of MLH1 and other downstream proteins \[[@B28-cancers-11-00598]\]. Several studies have reported that rs1800734 is associated with high levels of methylation and low levels of protein expression in different types of tumors \[[@B29-cancers-11-00598],[@B30-cancers-11-00598],[@B31-cancers-11-00598]\], which suggests that this polymorphism may contribute to gene dysfunction by altering transcription activity. The GG genotype carriers may be at a relatively low risk because the G-allele provides a favorable binding site for transcription factors, such as AP-4, which recruits RNA polymerase II and c-Myc, thereby leading to *MHL1* transcription \[[@B28-cancers-11-00598]\]. By contrast, a repressor protein may bind to the A-allele to recruit epigenetic modifying factors leading to promoter methylation and low level of *MHL1* transcription \[[@B29-cancers-11-00598]\]. Extensive promoter methylation was associated with *MLH1* inactivation \[[@B32-cancers-11-00598]\]. The AA genotype of *MLH1* rs1800734 was previously found to be correlated with poor prognosis in Taiwanese patients with lung cancer \[[@B27-cancers-11-00598]\]. Our findings support the proposition that reduced DNA damage efficacy offers a survival advantage in patients with OSCC.

A few studies have reported relatively poor survival outcomes in the *EXO1* rs1047840 and *MSH3* rs26279 GG genotypes among patients with HNSCC \[[@B14-cancers-11-00598],[@B16-cancers-11-00598]\]. Nogueira et al. reported that the GG genotypes of *EXO1* rs1047840 and *MSH3* rs26279 were associated with DFS and OS, respectively, in a Brazilian population with HNSCC. A similar Brazilian study on patients with HNSCC showed that the *MSH3* rs26279 GA or AA genotypes are associated with an approximate nine-fold higher risk of partial response to cisplatin chemoradiation or achieving stable disease than are patients with other genotypes \[[@B14-cancers-11-00598]\]. The *EXO1* rs1047840 GA genotype was associated with complete recovery in patients with laryngeal cancer treated using cisplatin and RT \[[@B33-cancers-11-00598]\]. However, we did not observe any association between the SNPs and clinical outcomes in our sample. The difference between the results of the previous study and those of the present study may be attributable to differences in ethnicity, tumor characteristics, treatment, and median follow-up times. Our sample was highly homogeneous and included patients with advanced OSCC of identical ethnicity who received identical treatment, whereas the study samples in the aforementioned studies consisted of patients with diverse tumor characteristics who received different treatment modalities. In addition, despite the long follow-up time of 199 months in our study, the median follow-up time in this study was shorter than that in other studies \[[@B14-cancers-11-00598],[@B16-cancers-11-00598]\] and could be attributed to the poor tumor characteristics of our patients. The difference in findings may also be attributed to the low statistical power of our study. Additional studies with larger samples than that in the present study may be required to confirm the results of the present study.

As previously reported \[[@B14-cancers-11-00598],[@B16-cancers-11-00598],[@B34-cancers-11-00598]\], we observed that the participants with ENE exhibited an increased risk of death and those with primary tumor size in the T3--T4 range and nodal involvement exhibited poorer DFS than their counterpart with milder characteristics. Epidemiological studies from Taiwan showed ethnic difference in oral cancer survival \[[@B35-cancers-11-00598],[@B36-cancers-11-00598]\]. Similarly, in our study mainland Chinese participants exhibited increased risk for recurrence than does participants of Taiwanese ethnicity.

The strength of our study is the relative homogeneity of our patient population with respect to ethnicity, treatment modality, and tumor stage, which eliminated the effects of differences in DNA damage and repair mechanisms and their effects on clinical outcomes. The relatively small sample owing to the strict inclusion criteria and the recruitment of patients from only one hospital may have limited the generalizability of our findings. Despite the aforementioned limitation, this is the first study to investigate the association between genetic polymorphisms in MMR genes and clinical outcomes in patients of Chinese ethnicity with advanced OSCC receiving adjuvant CCRT.

4. Materials and Methods {#sec4-cancers-11-00598}
========================

4.1. Ethical Statement {#sec4dot1-cancers-11-00598}
----------------------

The study was conducted in accordance with the Declaration of Helsinki. The ethics review committees of the Chang Gung Memorial Hospital (IRB No. 201800213B0) and the Taipei Medical University (IRB No. N201802083) granted final approval for the study. Written informed consent to participate in the study was obtained from all the participants after a detailed explanation of the study objectives.

4.2. Participants and Data Collection {#sec4dot2-cancers-11-00598}
-------------------------------------

For this study, participants were recruited from the Chang Gung Memorial Hospital, Linkou, Taiwan, and constituted a part of the Head and Neck Surgery Department's Cancer Registry from 1999 to 2016. The registry included 2528 cases of OSCC. After excluding 51 cases who had incomplete questionnaires, there were 973 cases who received surgery only, 513 cases who had surgery plus radiotherapy, 503 cases who had post-operative CCRT, and 488 cases who received other treatment or had missing information on treatment. We selected those patients who had received CCRT and restricted the sample to male subjects, which left a sample of 473 for the present study. Patients were further excluded if they had no blood specimen (*n* = 105), were of aboriginal ethnicity (*n* = 13), had early-stage OSCC (*n* = 12), had missing clinicopathological information (*n* = 12), or had failed the genotyping experiment (*n* = 7). Finally, 319 participants were included in the analysis. The sociodemographic data and lifestyle habits of the participants were obtained using an interviewer-administered questionnaire. The collected information included age, education level, ethnicity, lifestyle habits (history of alcohol drinking, betel quid chewing, and cigarette smoking), and family history of cancers. Lifestyle habits were dichotomized into never (never engaged in the habit for over 1 year continuously) and ever (had ever engaged in the habit for over 1 year continuously). Detailed clinical information was also collected by taking medical history, evaluating complete blood count, and conducting complete physical examination, routine blood chemistry tests, whole-body bone scan or positron emission tomography scan, abdominal ultrasound and magnetic resonance imaging (MRI), or computed tomography (CT) of the head and neck. The clinicopathological characteristics of the patients included tumor stage, depth, and differentiation, nodal status, and ENE, as well as perineural, skin, and bone invasions. The participants' weight and height were also recorded, and BMI was computed using the following formula: weight/height^2^ (kg/m^2^).

4.3. DNA Extraction and Genotyping {#sec4dot3-cancers-11-00598}
----------------------------------

Pairs of samples from the tumor and normal adjacent nontumor tissue that were previously obtained from each participant and stored in liquid nitrogen (at −80 °C) were used for pathological examination and staging by a pathologist. The Seventh Edition of the American Joint Committee on Cancer (AJCC)--TNM staging system \[[@B37-cancers-11-00598]\] was used for staging. Only participants diagnosed with histological squamous cell carcinoma and TNM stages III and IV were considered for the study. Prior to treatment, the participants' venous blood samples were collected and centrifuged, and buffer-coated cells were collected for DNA extraction. Genomic DNA extraction was performed using the standard phenol--chloroform method.

Extracted DNA was used for genotyping the *MSH2* SNP rs3732183, *MSH3* SNPs rs12515548 and rs26279, *EXO1* SNP rs1047840, and *MLH1* SNP rs1800734, which were selected based on their previously reported association with the risk or prognosis of cancers \[[@B14-cancers-11-00598],[@B16-cancers-11-00598],[@B19-cancers-11-00598],[@B20-cancers-11-00598]\]. The Sequenom iPLEX MassARRAY system (Sequenom, Inc., San Diego, CA, USA) was used for genotyping. Using the Sequenom MassARRAY platform and iPLEX GOLD chemistry, matrix-assisted laser desorption ionization time of flight (MALDI-TOF) spectroscopy was conducted. Then, 10 ng of genomic DNA was used as a template, and a polymerase chain reaction (PCR) mixture containing Qiagen HotStarTaq (Qiagen, Valencia, CA, USA) was prepared. Primer extension and cleanup using shrimp alkaline phosphatase were performed according to the Sequenom guidelines. The PCR primers were obtained from Integrated DNA Technology (Coralville, IA, USA). The MassARRAY Assay Design software Version 3.1 (Sequenom) was used for assay design. For quality control, 10% of samples were randomly selected, and genotypes showed 100% concordance for all SNPs.

4.4. Adjuvant CCRT and Follow-Up {#sec4dot4-cancers-11-00598}
--------------------------------

Prior to CCRT treatment, all the patients had undergone surgery that included radical tumor excision with neck dissection based on clinical stage after tumor survey. The primary tumor resection was performed at 1 cm above safety margins (both peripheral and deep margins), and neck dissection was performed according to examination status. All the patients received CCRT with radiation doses between 6000 and 6600 cGy, bi-weekly or tri-weekly intravenous cisplatin 40--60 m^2^/kg, and oral 5-fluorouracil for 4--8 weeks after the surgical procedure. The patients were evaluated during and after treatment through regular clinical and radiological examinations. The examinations involved check-ups every month for the first 6 months, every 2 months for the next 6 months, every 3 months within the second year, and every 6 months thereafter. Monitoring included analysis of medical history and physical examination (including complete oral examination), X-rays, CT or MRI, and laboratory examination. History of biopsy or imaging studies were used to confirm relapse, and deaths resulting from OSCC were recorded based on death certificates.

4.5. Statistical Analysis {#sec4dot5-cancers-11-00598}
-------------------------

The major clinical outcome was relapse (DFS) of OSCC or death (OS) caused by OSCC. The DFS time (in months) was calculated from the day of treatment commencement to the time of relapse, metastasis, or death from any cause. The OS time was defined as the duration (in months) between the time of treatment commencement and date of death. The patients who did not experience any event as of the date of the last follow-up visit were censored or subject to administrative censoring by the end of the study period (10 April 2019). The demographic and clinicopathological parameters of the participants were summarized using descriptive statistics. Cumulative survival in different genotypes was analyzed using Kaplan--Meier curves, and the differences between the genotypes were tested using the log-rank test. The association among the demographic and clinicopathological parameters, candidate SNPs, and OS or DFS were tested using univariate and multivariate Cox proportional hazard regression models. Multivariate analysis was conducted to examine the associations between individual SNPs and OS or DFS after adjusting for age and clinicopathological variables that were significant at *p* \< 0.10 in the univariate model. Different genetic models were used to test the effect of individual SNPs on OS and DFS (including codominant, additive, dominant, recessive, and allelic models). The most significant genetic model was finally used in the multivariate analysis. The relative risk of relapse or death was estimated using HR and their corresponding 95% CIs. For the two SNPs located in *MSH3*, LD analysis was performed using Haploview (version 4.2, Broad Institute, Cambridge, MA, USA). All analyses were two-sided, and *p* \< 0.05 was considered statistically significant. All analyses were conducted using the SAS software (version 9.4 for Windows; SAS Institute, Cary, NC, USA).

5. Conclusions {#sec5-cancers-11-00598}
==============

The strong association between MMR gene variants and clinical outcomes reported in our study supported the role of DNA MMR deficiency in OSCC progression. *MSH2* rs3732183 and *MLH1* rs1800734 may serve as predictors of OSCC survival and may influence the response to adjuvant CCRT treatment, particularly in patients with advanced stages of OSCC. Our findings may require confirmation through additional studies with relatively large samples or those conducted on patients of other ethnicities.

The authors are grateful to the study participants. We wish to acknowledge Wallace Academic Publishing for the English language review.

The following is available online at <https://www.mdpi.com/2072-6694/11/5/598/s1>, Figure S1: Linkage disequilibrium analysis between SNPs in *MSH3* (rs12515548 and rs26279).
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Kaplan--Meier analysis and log-rank test results of OS and DFS curves for the *MSH2* rs3732183 and *MLH1* rs1800734 polymorphisms in patients with oral squamous cell carcinoma treated with concurrent chemoradiotherapy. (**A-1**) No significant difference in OS among the *MSH2* rs3732183 genotypes (log-rank test *p =* 0.5185). (**A-2**) The GG genotype showed a borderline significant better DFS time than the AA genotype (log-rank test *p =* 0.0887). (**B-1,2**) No significant difference in death and recurrence among genotypes of *MLH1* rs1800734 (log-rank test *p =* 0.1911 and *p =* 0.1907, respectively).
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cancers-11-00598-t001_Table 1

###### 

Demographic and clinical characteristics of the patients with oral squamous cell carcinoma (OSCC) receiving adjuvant concurrent chemoradiotherapy.

  Variable                     Number (*n* = 319)   \%
  ---------------------------- -------------------- -------
  Mean age (SD), years         49.72 (9.8)          
  Age, years (≥50)             155                  48.59
  Ethnicity                                         
   Taiwanese                   230                  72.10
   Hakka                       72                   22.57
   Mainland Chinese            17                   5.33
  BMI, kg/m^2^                                      
   \<18.5                      22                   6.90
   18.5--23.9                  157                  49.22
   ≥24                         140                  43.89
  Smoking cigarettes (ever)    272                  85.27
  Drinking alcohol (ever)      221                  69.28
  Chewing betel quid (ever)    275                  86.21
  Drinking tea (ever)          156                  48.90
  Drinking coffee (ever)       76                   23.82
  Tumor differentiation \*                          
   Well                        51                   16.14
   Moderate                    210                  66.46
   Poor                        55                   17.40
  Primary tumor size                                
   T1--T2                      122                  38.24
   T3--T4                      197                  61.76
  Nodal involvement                                 
   N0                          38                   11.91
   N+                          281                  88.09
  Perineural invasion (yes)    177                  55.49
  Vascular invasion (yes)      19                   5.96
  Lymphatic invasion (yes)     40                   12.54
  Extranodal extension (yes)   205                  64.26
  Pathological TNM Stage                            
   III                         42                   13.17
   IV                          277                  86.83

BMI, body mass index; SD, standard deviation; TNM, tumor, nodes, and metastasis. \* Tumor cell differentiation in 3 patients were not available.

cancers-11-00598-t002_Table 2

###### 

Univariate association of demographic and clinical factors with survival in patients with OSCC receiving adjuvant concurrent chemoradiotherapy.

  Variable                No.   Event   OS                  Event         DFS                       
  ----------------------- ----- ------- ------------------- ------------- ----- ------------------- ----------
  Age, years                                                                                        
   \<50                   164   54      1.00                              69    1.00                
   ≥50                    155   40      0.71 (0.47--1.07)   0.104         60    0.82 (0.57--1.16)   0.262
  Ethnicity                                                                                         
   Taiwanese              230   69      1.00                              98    1.00                
   Hakka                  72    19      0.93 (0.56--1.56)   0.786         19    0.64 (0.39--1.04)   0.073
   Mainland Chinese       17    6       1.25 (0.54--2.88)   0.601         12    1.80 (0.99--3.29)   0.056
  BMI, kg/m^2^                                                                                      
   18.5--23.9             157   53      1.00                              66    1.00                
   \<18.5                 22    7       0.90 (0.41--1.97)   0.787         11    1.44 (0.76--2.72)   0.269
   ≥24                    140   34      0.66 (0.43--1.02)   0.058         52    0.82 (0.57--1.20)   0.306
  Smoking cigarettes                                                                                
   Never                  47    16      1.00                              20    1.00                
   Ever                   272   78      0.89 (0.51--1.53)   0.661         109   0.96 (0.59--1.57)   0.874
  Drinking alcohol                                                                                  
   Never                  98    31      1.00                              41    1.00                
   Ever                   221   63      1.00 (0.65--1.54)   0.994         88    1.00 (0.69--1.46)   1.000
  Chewing betel quid                                                                                
   Never                  44    13      1.00                              15    1.00                
   Ever                   275   81      0.96 (0.54--1.73)   0.900         114   1.37 (0.79--2.39)   0.268
  Drinking tea                                                                                      
   Never                  163   50      1.00                              63    1.00                
   Ever                   156   44      0.82 (0.55--1.24)   0.359         66    1.06 (0.75--1.51)   0.745
  Drinking coffee                                                                                   
   Never                  243   78      1.00                              93    1.00                
   Ever                   76    16      0.63 (0.37--1.07)   0.088         36    1.26 (0.85--1.86)   0.249
  Tumor differentiation                                                                             
   Well                   51    19      1.00                              24    1.00                
   Moderate               210   61      0.92 (0.55--1.53)   0.735         80    0.89 (0.56--1.42)   0.622
   Poor                   55    13      0.81 (0.40--1.63)   0.550         24    1.14 (0.64--2.02)   0.662
  Primary tumor size                                                                                
   T1--T2                 160   43      1.00                              59    1.00                
   T3--T4                 159   51      1.41 (0.93--2.13)   0.102         70    1.47 (1.03--2.09)   0.034 \*
  Nodal involvement                                                                                 
   N0--N1                 102   19      1.00                              35    1.00                
   N2--N3                 217   75      2.38 (1.43--3.94)   0.0008 \*     94    1.76 (1.17--2.63)   0.006 \*
  Perineural invasion                                                                               
   No                     142   41      1.00                              56    1.00                
   Yes                    177   53      1.15 (0.77--1.74)   0.493         73    1.19 (0.83--1.70)   0.340
  Vascular invasion                                                                                 
   No                     300   86      1.00                              122   1.00                
   Yes                    19    8       1.51 (0.73--3.13)   0.266         7     0.94 (0.44--2.02)   0.876
  Lymphatic invasion                                                                                
   No                     279   75      1.00                              110   1.00                
   Yes                    40    19      2.22 (1.32--3.72)   0.003 \*      19    1.37 (0.82--2.30)   0.224
  Extranodal extension                                                                              
   No                     114   14      1.00                              36    1.00                
   Yes                    205   80      3.78 (2.14--6.68)   \<0.0001 \*   93    1.87 (1.26--2.78)   0.002 \*
  Pathologic TNM Stage                                                                              
   III                    42    10      1.00                              14    1.00                
   IV                     277   84      1.62 (0.83--3.15)   0.154         115   1.66 (0.93--2.94)   0.086

BMI, body mass index; HR, hazard ratio; CI, confidence interval; OS, overall survival; DFS, disease-free survival. \* Significance at *p* \< 0.05.

cancers-11-00598-t003_Table 3

###### 

Univariate association between candidate single-nucleotide polymorphisms (SNPs) in mismatch repair (MMR) genes and survival in patients with OSCC receiving concurrent chemoradiotherapy.

  Variable   No.              Event             OS         DFS                                                  
  ---------- ---------------- ----------------- ----- ---- ------------------- ------- ---- ------------------- ----------
  MSH2                                                                                                          
             rs3732183 ^a^                                                                                      
                              AA                150   44   1.00                        61   1.00                
                              AG                125   36   0.94 (0.60--1.46)   0.779   54   1.02 (0.70--1.49)   0.913
                              GG                34    8    0.64 (0.30--1.37)   0.253   8    0.47 (0.22--0.97)   0.042 \*
                              Additive model               0.85 (0.62--1.18)   0.337        0.81 (0.62--1.06)   0.120
                              Dominant model    154   44   0.87 (0.57--1.32)   0.507   62   0.88 (0.61--1.26)   0.481
                              Recessive model   34    8    0.66 (0.32--1.37)   0.268   8    0.46 (0.22--0.94)   0.034 \*
                              G-allele                     0.84 (0.61--1.16)   0.290        0.79 (0.60--1.05)   0.102
  MSH3                                                                                                          
             rs12515548 ^a^                                                                                     
                              CC                183   55   1.00                        73   1.00                
                              CT                122   35   0.93 (0.61--1.43)   0.742   49   1.02 (0.71--1.48)   0.909
                              TT                13    3    0.83 (0.26--2.67)   0.760   6    1.44 (0.63--3.33)   0.391
                              Additive model               0.93 (0.64--1.33)   0.676        1.09 (0.80--1.48)   0.590
                              Dominant model    135   38   0.92 (0.61--1.40)   0.703   55   1.06 (0.74--1.51)   0.764
                              Recessive model   13    3    0.86 (0.27--2.72)   0.795   6    1.43 (0.63--3.26)   0.395
                              T-allele                     0.93 (0.66--1.32)   0.691        1.08 (0.81--1.44)   0.610
             rs26279                                                                                            
                              AA                184   55   1.00                        74   1.00                
                              AG                122   36   0.97 (0.64--1.48)   0.885   49   1.02 (0.71--1.48)   0.906
                              GG                13    3    0.78 (0.24--2.49)   0.671   6    1.30 (0.56--2.98)   0.544
                              Additive model               0.94 (0.66--1.34)   0.729        1.07 (0.79--1.45)   0.675
                              Dominant model    135   39   0.95 (0.63--1.44)   0.812   55   1.05 (0.73--1.49)   0.800
                              Recessive model   13    3    0.79 (0.25--2.49)   0.683   6    1.28 (0.56--2.92)   0.552
                              G-allele                     0.94 (0.67--1.33)   0.741        1.06 (0.79--1.42)   0.689
  EXO1                                                                                                          
             rs1047840 ^a^                                                                                      
                              GG                219   59   1.00                        91   1.00                
                              GA                93    31   1.34 (0.86--2.07)   0.198   33   0.85 (0.57--1.28)   0.438
                              AA                6     3    2.84 (0.88--9.14)   0.081   4    2.68 (0.97--7.36)   0.056
                              Additive model               1.43 (0.98--2.10)   0.067        1.02 (0.71--1.46)   0.934
                              Dominant model    99    34   1.40 (0.92--2.15)   0.121   37   0.92 (0.62--1.36)   0.683
                              Recessive model   6     3    2.59 (0.81--8.27)   0.108   4    2.80 (1.02--7.66)   0.045 \*
                              A-allele                     1.39 (0.96--2.00)   0.078        1.02 (0.72--1.43)   0.937
  MLH1                                                                                                          
             rs1800734                                                                                          
                              AA                100   36   1.00                        44   1.00                
                              AG                168   46   0.74 (0.47--1.14)   0.170   70   0.91 (0.62--1.33)   0.611
                              GG                51    12   0.61 (0.32--1.17)   0.137   15   0.59 (0.33--1.06)   0.077
                              Additive model               0.77 (0.56--1.04)   0.092        0.80 (0.62--1.04)   0.098
                              Dominant model    219   58   0.70 (0.46--1.07)   0.101   85   0.82 (0.57--1.19)   0.302
                              Recessive model   51    12   0.73 (0.40--1.34)   0.312   15   0.63 (0.36--1.07)   0.089
                              G-allele                     0.78 (0.58--1.05)   0.104        0.81 (0.63--1.05)   0.106

HR, hazard ratio; CI, confidence interval; OS, overall survival; DFS, disease-free survival. **^a^** Values is less than the total due to missing variables. \* Significance at *p* \< 0.05.

cancers-11-00598-t004_Table 4

###### 

Multivariate association between polymorphisms of MMR pathway genes and survival in patients with OSCC receiving adjuvant concurrent chemoradiotherapy.

  Variable               OS                  DFS                             
  ---------------------- ------------------- ----------- ------------------- ----------
  Age, years                                                                 
   \<50                  1.00                            1.00                
   ≥50                   0.78 (0.51--1.19)   0.243       0.94 (0.65--1.36)   0.726
  Ethnicity                                                                  
   Taiwanese                                             1.00                
   Hakka                 \-                              0.68 (0.39--1.16)   0.158
   Mainland Chinese      \-                              1.99 (1.04--3.82)   0.039 \*
  BMI kg/m^2^                                                                
   18.5--23.9            1.00                                                
   \<18.5                0.97 (0.44--2.17)   0.946       \-                  
   ≥24                   0.73 (0.46--1.15)   0.175       \-                  
  Drinking coffee                                                            
   Never                 1.00                                                
   Ever                  0.67 (0.39--1.17)   0.157       \-                  
  Primary tumor size                                                         
   T1--T2                                                1.00                
   T3--T4                \-                              1.88 (1.19--2.98)   0.007 \*
  Nodular involvement                                                        
   N0--N1                1.00                            1.00                
   N2--N3                1.63 (0.96--2.79)   0.072       1.96 (1.04--3.69)   0.038 \*
  Lymphatic invasion                                                         
   No                    1.00                                                
   Yes                   1.56 (0.91--2.66)   0.105       \-                  
  Extranodal extension                                                       
   No                    1.00                            1.00                
   Yes                   2.91 (1.58--5.34)   0.0006 \*   1.38 (0.87--2.20)   0.172
  Pathologic TNM Stage                                                       
   III                                                   1.00                
   IV                    \-                              0.66 (0.27--1.66)   0.380
  MSH2 rs3732183                                                             
   AA                                                    1.00                
   AG                    \-                              0.97 (0.65--1.44)   0.872
   GG                    \-                              0.45 (0.22--0.96)   0.039\*
  EXO1 rs1047840                                                             
   GG                    1.00                            1.00                
   GA                    1.16 (0.73--1.83)   0.532       0.83 (0.54--1.29)   0.411
   AA                    2.36 (0.72--7.80)   0.159       1.15 (0.34--3.88)   0.818
  MLH1 rs1800734                                                             
   AA                    1.00                            1.00                
   AG                    0.67 (0.42--1.07)   0.091       0.74 (0.49--1.12)   0.158
   GG                    0.52 (0.27--1.01)   0.054       0.49 (0.26--0.92)   0.028 \*

BMI, body mass index; HR, hazard ratio; CI, confidence interval, OS, overall survival; DFS, disease-free survival. \* Significance at *p* \< 0.05.
